Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Brengitecan vs Pembrolizumab-Chemo in First-line HER2-mutant NSCLC
NCT07178795Phase 3Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Sep 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of BL-M07D1 in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) (2 arms), sponsored by Biokin Pharmaceutical. Primary endpoint: Progression-free survival at 24 months. Started Sep 2025; status: recruiting.
02
Drugs
BL-M07D1
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT07178795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07178795.